Sep 14, 2026 7:00 am EDT Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
Sep 13, 2026 5:00 pm EDT Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
Sep 10, 2026 7:00 am EDT Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
Sep 8, 2026 7:00 am EDT Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
Aug 26, 2026 7:01 am EDT Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Aug 12, 2026 7:00 am EDT Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Aug 6, 2026 4:01 pm EDT Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights